Vaxcyte, Inc. $PCVX Shares Purchased by Jennison Associates LLC

Jennison Associates LLC increased its stake in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 24.3% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,399,299 shares of the company’s stock after purchasing an additional 273,579 shares during the period. Jennison Associates LLC owned 1.08% of Vaxcyte worth $45,491,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. AlphaQuest LLC acquired a new position in shares of Vaxcyte during the 1st quarter worth approximately $33,000. BI Asset Management Fondsmaeglerselskab A S acquired a new position in Vaxcyte in the 1st quarter valued at $35,000. IFP Advisors Inc boosted its holdings in shares of Vaxcyte by 376.4% during the first quarter. IFP Advisors Inc now owns 1,653 shares of the company’s stock worth $62,000 after purchasing an additional 1,306 shares during the last quarter. CWM LLC boosted its holdings in shares of Vaxcyte by 197.3% during the second quarter. CWM LLC now owns 1,680 shares of the company’s stock worth $55,000 after purchasing an additional 1,115 shares during the last quarter. Finally, Advisors Asset Management Inc. boosted its holdings in shares of Vaxcyte by 81.6% during the first quarter. Advisors Asset Management Inc. now owns 1,929 shares of the company’s stock worth $73,000 after purchasing an additional 867 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. The Goldman Sachs Group assumed coverage on Vaxcyte in a report on Friday, September 12th. They set a “neutral” rating and a $38.00 price objective on the stock. Cowen restated a “buy” rating on shares of Vaxcyte in a report on Thursday, August 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a report on Tuesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $106.25.

Vaxcyte Stock Up 2.8%

PCVX stock opened at $44.75 on Friday. The company has a market cap of $5.81 billion, a price-to-earnings ratio of -10.89 and a beta of 1.12. The business has a fifty day simple moving average of $36.73 and a 200-day simple moving average of $34.50. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $116.00.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.10). During the same period last year, the business posted ($1.10) earnings per share. As a group, analysts expect that Vaxcyte, Inc. will post -4.21 earnings per share for the current fiscal year.

Vaxcyte Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.